Key Points
- To review the mechanisms driving chemotherapy- and immunotherapy-induced atherosclerosis and outline interdisciplinary strategies for managing cardiovascular complications in cancer patients.
- Narrative synthesis of clinical mechanisms underlying treatment-induced cardiotoxicity and vascular injury in cancer care.
- Evaluation of vascular risks associated with angiogenesis inhibitors, vascular endothelial growth factor (VEGF) signaling, and immune checkpoint inhibitors.
- Prolonged survival and older demographics among cancer patients are linked to increased rates of cardiotoxicity, particularly atherosclerotic lesions.
- Targeting vascular endothelial growth factors via angiogenesis inhibitors modifies tumor immune microenvironments but compounds vascular risk during combination immunotherapy.
- Continuous, long-term involvement of onco-cardiologists is necessary to mitigate therapy-related arterial disease without compromising oncologic efficacy.
Structured PICO
PPopulationPatients with cancer receiving chemotherapeutic and immunotherapeutic treatments, particularly angiogenesis inhibitors and immune checkpoint inhibitors.
Highlights the increasing necessity for onco-cardiologists to manage long-term cardiovascular complications, specifically atherosclerosis, arising from modern cancer therapies.